Litcius/Paper detail

Post-endotoxin exposure-induced lung inflammation and resolution consequences beneficially impacted by lung-delivered IL-10 therapy

Jill A. Poole, Rohit Gaurav, Aaron Schwab, Amy Nelson, Angela Gleason, Debra J. Romberger, Todd A. Wyatt

2022Scientific Reports24 citationsDOIOpen Access PDF

Abstract

Abstract Although lung diseases typically result from long-term exposures, even a robust, one-time exposure can result in long-lasting consequences. Endotoxin is a ubiquitous environmental/occupational inflammatory agent often used to model airway inflammation. Using a murine model, the return to lung homeostasis following high dose inhalant lipopolysaccharide (LPS, 10–100 μg) exposure were delineated over 2 weeks. LPS-induced rapid weight loss, release of proinflammatory mediators, and inflammatory cell influx with prolonged persistence of activated macrophages CD11c + CD11b + and recruited/transitioning CD11c int CD11b + monocyte-macrophages out to 2 weeks. Next, lung-delivered recombinant (r) interleukin (IL)-10 was intratracheally administered for 3 doses initiated 5 h following LPS (10 μg) exposure for 2 days. IL-10 therapy reduced LPS-induced weight loss and increased blood glucose levels. Whereas there was no difference in LPS-induced bronchoalveolar lavage airway fluid cellular influx, total lung cell infiltrates were reduced (37%) with rIL-10 treatment. Post-LPS exposure treatment with rIL-10 strikingly reduced lavage fluid and lung homogenate levels of tumor necrosis factor-α (88% and 93% reduction, respectively), IL-6 (98% and 94% reduction), CXCL1 (66% and 75% reduction), and CXCL2 (47% and 67% reduction). LPS-induced recruited monocyte-macrophages (CD11c int CD11b + ) were reduced (68%) with rIL-10. Correspondingly, LPS-induced lung tissue CCR2 + inflammatory monocyte-macrophage were reduced with rIL-10. There were also reductions in LPS-induced lung neutrophils, lymphocyte subpopulations, collagen content, and vimentin expression. These findings support the importance of studying resolution processes for the development of treatment after unintended environmental/occupational biohazard exposures. Short-term, lung-delivered rIL-10 favorably hastened inflammatory recovery processes following acute, high dose inhalant LPS exposure.

Topics & Concepts

MedicineLungBronchoalveolar lavageImmunologyProinflammatory cytokineInflammationCD11cLipopolysaccharideMonocyteTumor necrosis factor alphaCXCL1Internal medicineChemokineChemistryGenePhenotypeBiochemistryRespiratory Support and MechanismsAsthma and respiratory diseasesImmune Response and Inflammation